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Abstract
Purpose Health technology assessment (HTA) coverage
recommendations differ across countries for the same
drugs. Unlike previous studies, this study adopts a mixed
methods research design to investigate, in a systematic
manner, these differences.
Methods HTA recommendations for ten orphan drugs
appraised in England (NICE), Scotland (SMC), Sweden
(TLV) and France (HAS) (N = 35) were compared using a
validated methodological framework that breaks down
these complex decision processes into stages facilitating
their understanding, analysis and comparison, namely: (1)
the clinical/cost-effectiveness evidence, (2) its interpreta-
tion (e.g. part of the deliberative process) and (3) influence
on the final decision. This allowed qualitative and quanti-
tative identification of the criteria driving recommenda-
tions and highlighted cross-country differences.
Results Six out of ten drugs received diverging HTA rec-
ommendations. Reasons for cross-country differences
included heterogeneity in the evidence appraised, in the
interpretation of the same evidence, and in the different
ways of dealing with the same uncertainty. These may have
been influenced by agency-specific evidentiary, risk and
value preferences, or stakeholder input. ‘‘Other considera-
tions’’ (e.g. severity, orphan status) and other decision
modulators (e.g. patient access schemes, lower discount
rates, restrictions, re-assessments) also rendered uncer-
tainty and cost-effectiveness estimates more acceptable.
The different HTA approaches (clinical versus cost-effec-
tiveness) and ways identified of dealing with orphan drug
particularities also had implications on the final decisions.
Conclusions This research contributes to better under-
standing the drivers of these complex decisions and why
countries make different decisions. It also contributed to
identifying those factors beyond the standard clinical and
cost-effectiveness tools used in HTA, and their role in
shaping these decisions.
Keywords Health technology assessment  Orphan drugs 
France  England  Scotland  Sweden  Mixed methods
research  Thematic analysis
Introduction
Providing equal access to affordable medicines across
countries is high on the political agenda in many OECD
countries including those in the European Union [1]. In
reality, this is far from being achieved even in countries
with similar or comparable policies, rules or priorities. In
countries using health technology assessment (HTA) to
inform resource allocation decisions, important disparities
across countries in their HTA coverage recommendations
for the same drug are often reported [2–4]. These diver-
gences may relate to contextual differences such as the
objectives adopted, where it might be a pharmacoepi-
demiological study in one country and a systematic review
of all aspects of using a technology in another [5]. Equally,
there may be different willingness-to-pay thresholds
affecting the extent to which an HTA outcome is accept-
able [6, 7]. Differences may also be due to controversies
over the HTA process itself, including questions about the
most appropriate methodological approach to undertaking
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HTA [8, 9], the application of HTA in each setting, whe-
ther the measures used fully capture the effects and costs
from taking the treatment [10–12], what levels of evidence
are acceptable [13, 14], how to deal with uncertainty [15],
or to what extent ‘‘other considerations’’, e.g. disease and
treatment characteristics, were consistent across decisions
[16].
This problem, together with its implications, has been
identified and possible explanations examined. Eight
studies compared HTA drug coverage recommendations
across countries and highlighted the extent of these dif-
ferences [2, 3, 17–22]. Their research designs were in the
form of retrospective descriptive or cohort analyses, and
countries compared included Canada, Australia, England,
Scotland, France and New Zealand. The reasons for cross-
national differences were also explored, but with varying
levels of thoroughness. Morgan and colleagues focused on
the transparency and rigour of the processes rather than on
case-specific reasons for diverging recommendations [17].
Three other studies investigated the reasons for these dif-
ferences [2, 3, 18], but relied on few cases or potential
reasons. First, they did not outline the key determinants or
structure of the decision-making explored, where the rea-
sons set forth may not constitute the full picture. Second,
issues relating to the clinical and pharmacoeconomic
assessments were identified. However, the level of detail
provided in their assessments did not differentiate for the
type of uncertainty, how they were dealt with and what
factors influenced these processes across settings. Third,
the methodological approaches used were not sufficiently
detailed for these approaches to be transferable. Given that
these decision processes are complex and understanding
what happened for the same drug in different countries may
be challenging, a more systematic, structured and com-
prehensive approach to identifying and comparing differ-
ences would be required. Additionally, understanding how
similar scenarios were dealt with across settings may also
constitute a way forward to identify limitations in applying
HTA and learn from how these were dealt with across
settings [4].
Through the application of a validated mixed methods
framework [4], the objectives of this study were twofold: to
systematically investigate the drivers of HTA recommen-
dations for a sample of orphan drugs in four countries, and
to identify the reasons for cross-country differences. The
subject matter of the analysis was orphan drugs as they are
often cost-ineffective due to the small patient numbers,
heterogeneous nature of the conditions they treat, and their
often high acquisition price [23–26]. Different studies
nevertheless demonstrated that orphan drugs receive the
same or a higher level of acceptance compared to other
drugs treating more prevalent disease areas [27–29]. Spe-
cial attention was given to understanding the level of
uncertainty characterising orphan drugs, how it was dealt
with, and how disease and drug-specific characteristics
were accounted for.
Methods
Sampling of study countries and drug-indication
pairs
Four of the most well-established European HTA bodies
were included in the study based on purposive sampling [4],
which use clinical or cost-effectiveness as decision-making
criteria and for which the reports stating the HTA recom-
mendation and reasons were publicly available. These
included the National Institute for Health and Care Excel-
lence (NICE) in England, the Scottish Medicines Consor-
tium (SMC) in Scotland, the Dental and Pharmaceutical
Benefits Board (TLV) in Sweden and the Haute Autorite´ de
Sante´ (HAS) in France. The conventional HTA processes
for both orphan and non-orphan indications were examined.
The study countries make no differentiation of drugs’
orphan status, with the exception of the SMC and its SMC
modifiers. SMC will accept more uncertainty in the health
economic case or higher cost/QALYs for orphan drugs.
Additional factors, e.g. the SMC modifiers, are considered
when assessing the acceptability of uncertainty and high
incremental cost-effectiveness ratios (ICERs) [30].
All drug-indication pairs with an orphan designation
from the European Medicines Agency (EMA) [31] and
appraised by NICE through the Single Technology
Appraisal process until December 2012 were included and
recorded by their indication, generic name and HTA rec-
ommendation. The HTA recommendation was categorised
as to list, restrict or reject a drug for coverage. The decision
by HAS relies on the drug’s medical benefit (SMR) driving
the coverage rate (e.g. 65, 35, 15 %) and the relative
improvement in medical benefit (ASMR) providing the
price fixing regime applicable, ranging from major to
insufficient. Two hundred and sixty-nine technology
appraisal reports were published up to December 2012 by
NICE, 23 of which received an orphan EMA designation.
Excluded were those that underwent the multiple technol-
ogy appraisal process or were terminated at the time of data
collection at NICE (9/23), and those that were appraised by
fewer than three of the four study countries (4/23). Those
compounds that underwent the abbreviated procedure at
SMC were not included since the rationale for the decision
was not available. Ten unique orphan drug-indication pairs
and a total of 35 country and drug-indication pairs were
selected (Table 1). Only five were included by TLV, which
appraised mainly outpatient drugs at the time of the study,
while many of the study drugs were inpatient [32].
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Study design and methodological framework
Mixed methods were used to systematically examine the
HTA decision processes for individual drugs and countries
on the basis of a validated methodological framework. The
approach used was an exploratory sequential mixed meth-
ods design, where the qualitative strand took priority and
preceded the quantitative strand. The framework consisted
in a coding manual and case study template [4]. This
allowed breaking down of HTA decisions into different
stages facilitating their understanding, analysis and com-
parison in terms of: (a) the clinical and/or cost-effectiveness
evidence appraised, (b) the interpretation of this evidence
(e.g. as part of the deliberative process) and (c) their
influence on the final recommendation (Fig. 1 ) [4].
This multi-level research design allowed for an in-depth
analysis of the criteria driving these decision-making pro-
cesses and of their role in shaping these decision processes
in each country, and whether they explained cross-national
differences. This research did not aim to generalise find-
ings, but was interested in exploring and elucidating the
reasons behind the HTA decisions, which are mainly
qualitative in nature [33]. The quantitative strand aimed to
complement and enhance the interpretation of the qualita-
tive findings, and to produce more structured data to be
used for subsequent analyses.
Data analysis
Data sources comprised publicly available HTA reports,
other official documents (e.g. memos in Sweden) and
comments from competent authorities. Although the aims
of the HTA reports differ (e.g. advice versus decision), they
were assumed to be transparent and reflect the key deter-
minants driving the recommendations [34]. The main
results were presented to, and discussed with the HTA
Table 1 List of drug-indication pairs included in the study
Generic/brand name Indication NICE
England
SMC
Scotland
TLV
Sweden
HAS—Francea
SMR (coverage)
ASMR (pricing)
Eltrombopag
REVOLADE
Chronic idiopathic thrombocytopenic purpura DNL LWC LWC Important (65 %)
II (EU)
Romiplostim
NPLATE
Chronic idiopathic thrombocytopenic purpura LWC LWC LWC Important (65 %)
II (EU)
Everolimus
AFINITOR
Renal cell carcinoma (2nd line, advanced) DNL DNL L Important (100 %)
IV (comp)
Lenalidomide
REVLIMID
Multiple myeloma (3rd line) LWC LWC L Important (65 %)
III (EU)
Mifamurtide
MEPACT
Osteosarcoma LWC L LWC Insufficient (0 %)
DNL
Azacitidine
VIDAZA
Myelodysplastic syndrome LWC LWC NA Important (65 %)
II (EU)
Imatinib
GLIVEC
Gastro intestinal stromal tumour (adjuvant, after surgery) DNL LWC NA Important (100 %)
III (EU)
Mannitol dry
BRONCHITOL
Cystic fibrosis LWC DNL NA Weak (15 %)
V (comp)
Ofatumumab
ARZERRA
Chronic lymphocytic leukemia DNL DNL NA Moderate (35 %)
V (comp)
Trabectedin
YONDELIS
Soft tissue sarcoma LWC DNL NA Important (65 %)
V (comp)
NICE National Institute for Health and Care Excellence (NICE), SMC Scottish Medicines Consortium, TLV Dental and Pharmaceutical Benefits
Board, HAS Haute Autorite´ de Sante´, L list, LWC list with restrictions, DNL do not list, NA not applicable, EU price negotiation at European price
levels, comp price set below comparator price
a The ASMR (Ame´lioration du Service Me´dical Rendu) ranks drugs according to their relative improvement in clinical benefit in five levels,
from a major innovation (level I) to no improvement (level V). The pricing scheme is determined by the ASMR ranking [e.g. ASMR I–
III = price negotiations within European price levels (EU), ASMR IV–V = price set below comparators (comp)]. The SMR (Service Me´dical
Rendu) ranks the drug according to the drug’s clinical benefit in four levels (insufficient, weak, moderate, important) and drives the coverage rate
(0, 15, 35, 65 %)
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bodies. Results were also regularly presented to HTA
experts (e.g. Advance-HTA consortium) at various occa-
sions, where feedback was collected. This contributed to
ensuring that the interpretation of the decisions made by
the researcher was accurate.
Qualitative analysis was conducted in the first stage of
the research. On the basis of the framework, all the relevant
information at each step of the decision process was
identified. This information was compiled into existing
case study forms to ensure its completeness and compa-
rability across countries. Thematic analysis was undertaken
to code this information in the HTA reports using the
NVivo 10 software [35]. Coding was flexible and iterative
with new codes being created for all newly identified cri-
teria and included in the coding manual with their defini-
tion and coding rule, ensuring that the multiple dimensions
of the decision-making process were captured. The HTA
reports already coded were re-examined with these new
codes, and adjustments were made if necessary. Intra-
coding reliability was tested for consistency of coding, and
content validity for the representativeness and homogene-
ity of the information coded within codes [36]. The data
collected was exported into excel for analysis using dif-
ferent coding matrix queries.
The qualitative data collected were transformed into
quantitative categorical nominal variables by exporting the
data into Stata 13 [37]. Thematic matrixes and descriptive
statistics were used to determine types and frequencies of
variables, their influence on the final recommendation, and
how they compared across countries. Correspondence
analysis was used to measure agency-specific risk prefer-
ences derived from the types of uncertainty, and value
preferences derived from the ‘‘other considerations’’ iden-
tified [38, 39]. It allowed measurement of the associations
between these variables using the chi-squared statistic test
of independence and facilitated the understanding of these
complex relationships in a bi-dimensional graphical rep-
resentation [40]. For comparability purposes, TLV was not
included in this first part of the analysis but in a secondary
analysis relying on the five drugs commonly appraised by
all.
Descriptive statistics were used to measure the fre-
quency of agreement across countries in their interpretation
of the evidence. Cohen’s kappa scores of cross-country
agreement levels were measured to check the robustness of
the results obtained by the primary metric, and was done so
in a comparable manner given that it focused on each
individual concern (uncertainty) raised that was common
across settings [41]. Two categories of agreement were
measured: (a) the issues raised by each agency about the
same evidence, and (b) how the same issues raised by at
least two agencies were dealt with across settings. This
allowed comparison of observed agreement with agree-
ment expected by chance, ranging from poor (j = 0) to
Fig. 1 Methodological framework [4] applied to systematically
compare HTA decision processes across countries. The HTA process
was divided into 3 stages: the evidence appraised (e.g. trial type,
clinical and safety endpoints, comparators, economic models), the
interpretation of this evidence (e.g. nature of uncertainty, how it was
dealt with and the influence of stakeholder input and ‘‘other
considerations’’) and their influence on the final recommendation.
Uncertain evidence was defined as evidence considered not fully
capturing the effects of a treatment in the intended population by the
assessors. ‘‘Other considerations’’ was defined as the non-quantifiable
or non-quantified considerations relating to treatment or disease
characteristics not captured by routine methods of HTA (e.g. QALY).
A number of criteria considered at each stage of the process were
qualitatively collected, and quantitatively analysed to determine the
criteria driving these decisions (vertical component) and the reasons
for differences across countries (horizontal component) [4]
E. Nicod
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perfect agreement (j = 1), and where negative values of j
correspond to cases when agreement was less than that
expected by chance [42].
Finally, the analysis also aimed to identify those issues
or considerations that relate to the rarity of these condi-
tions, and understand and compare the different approaches
to dealing with them across settings.
Results
Six of the ten study drugs received diverging recommen-
dations, e.g. positive or restricted in some countries and
rejected in others (Table 1). Out of the four remaining
cases with homogeneous recommendations, romiplostim
and lenalidomide were restricted in their indications in
some countries and not in others, and ofatumumab was
rejected by NICE and SMC and received the lowest ASMR
V rating with a moderate SMR rating (30 % reimburse-
ment rate). In only one case (azacitidine) were the rec-
ommendations issued really similar. Contrasting trends
were also seen, where, for example, mifamurtide received a
positive recommendation from NICE and SMC, but was
considered insufficient and rejected by HAS. This rarely
occurs in France as most drugs considered not to provide
any additional benefit would receive an ASMR V rating.
Another contrast between the recommendations issued
based on cost-effectiveness and those based on clinical
benefit (HAS) was seen for eltrombopag and imatinib,
which received high ratings in France (important SMR and
ASMR II–III), but were rejected and restricted by NICE
and SMC, respectively. These examples emphasise the
magnitude and contradictory nature of these differences.
Implications for patients and society are significant in
terms of access and efficiency in the use of healthcare
resources. Results describe the similarities and differences
identified at each stage of the decision process, how they
compare across countries and contribute to explaining
cross-country differences.
Evidence
The same primary trials were considered, which were
predominantly phase III RCTs for eight of the study drugs.
For the two remaining drugs, the primary trials were phase
II due to the early marketing authorisation received (e.g.
trabectedin, ofatumumab). These primary trials had rela-
tively small sample sizes (e.g. less than 300 participants in
60 % of trials) and decisions often relied on results from
subgroup analyses (e.g. 50 % of cases). Comparators were
standard care except two cases comparing different doses
of the treatment under investigation (e.g. mannitol dry,
trabectedin) and one case with no comparator (e.g.
ofatumumab). For 80 % of the study drugs, the primary
endpoints were surrogate and predominantly validated with
the exception of ‘‘time-to-progression’’ for soft tissue sar-
coma and ‘‘platelet response’’ for idiopathic thrombocy-
topenic purpura. In two cases, NICE’s main outcome of
interest was ‘‘overall survival’’ despite it not being the
trial’s primary endpoint (e.g. imatinib, ofatumumab).
The inclusion of the remaining non-primary trials had
very little influence on the assessment. Outcomes from
these trials were generally not reported, and when reported,
the type of data provided was around safety (e.g. romi-
plostim, ofatumumab, eltrombopag), dosage research (e.g.
eltrombopag) and historical controls (e.g. trabectedin).
Focusing on the economic evidence, similar cost-utility
models were considered by NICE, SMC and TLV except
for eltrombopag, for which a cost-minimisation analysis
was considered by TLV. Additionally, the comparators
used by NICE and SMC for eltrombopag were different:
NICE considered conventional care, while SMC and TLV
considered romiplostim. No cost-effectiveness models
were included in the HAS reviews, as cost-effectiveness
was not a requirement for first time approvals at the time of
the study.
Different evidence was included by some agencies and
not by others. When comparing the trials considered by
NICE to those considered by SMC, TLV and HAS, 1 out of
19 trials, 4 out of 15, and 6 out of 23, respectively, were not
included in the NICE appraisals. These included a database
used to estimate HRQol data for trabectedin for SMC; two
open-label trials (eltrombopag) and two registries (romi-
plostim) for TLV; and four phase II open-label trials
(azacitidine, eltrombopag), one post-marketing surveil-
lance survey (study extension for eltrombopag) and one
indirect comparison (trabectedin) for HAS. HRQol data
was not specifically reported in five out of ten cases, and in
four other cases, it was not reported homogeneously across
the board.
These differences in the evidence appraised were asso-
ciated with differing HTA outcomes in five cases
(Table 2): (a) the inclusion of registry data for trabectedin
by NICE as historical controls; (b) different primary end-
points for mifamurtide (‘‘overall survival’’ for NICE and
‘‘progression-free survival’’ for SMC, TLV and HAS);
(c) the secondary endpoint ‘‘severe bleeding events’’ for
eltrombopag only reported by NICE; (d) the lack of HRQol
data in the assessment of eltrombopag for HAS; and
(e) different economic models for eltrombopag.
Interpretation of the evidence
When appraising the evidence, a number of concerns were
raised and recorded in the HTA reports. This ‘‘uncertainty’’
was identified 124 times (Nu) and grouped into ten
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Table 2 Cases where differences at each step of the HTA process explain differences in HTA recommendations
Drug and indication pair Eltrombopag Imatinib Mannitol dry Mifamurtide Trabectedin
Idiopathic
thrombocytopenic
purpura
Gastro intestinal
stromal tumours
(adjuvant, after
surgery)
Cystic fibrosis Osteosarcoma Soft tissue
sarcoma
HTA
recommendation
Positively
appraised (list
or restricted)
SMC, TLV, HAS
(ASMR II)
SMC, HAS
(ASMR III)
NICE, HAS
(ASMR V)
NICE, SMC,
TLV
NICE, HAS
(ASMR V)
Rejected NICE NICE SMC HAS SMC
Evidence Differences in
the level of
evidence
reported
 Severe bleeding
events (WHO
grade 3–4)
(NICE)
 Lack of Qol data
(HAS)
Qol data included
for NICE, SMC
and TLV
 CUA-standard
care (NICE)
4 CUA-
romiplostim
(SMC)
4 CMA-
romiplostim
(TLV)
4 Progression-
free survival =
primary
endpoint
(SMC, TLV,
HAS)
 Overal
survival =
primary
endpoint
(NICE)
4 Use of registry
data as
historical
controls
(NICE)
Interpretation of
the evidence
Different
interpretation
of the same
evidence
appraised
Short trial duration
 NICE, SMC
Not raised by HAS
No reduction in
hospital days and
use of antibiotics
 HAS
Not raised by SMC,
NICE
Qol not improved
 HAS
4 NICE
Not raised by SMC
Different
interpretation
of the same
uncertainty
Short trial duration
 NICE (experts),
SMC, TLV
4 HAS (same as
comparator)
Overall survival
not
significantly
improved
 NICE
4 SMC (orphan)
4 HAS (on-going
trial)
Risk of
bronchospasms
 HAS
4 NICE (expert
opinion)
Not raised by SMC
Risk of
interaction
between
treatments
 HAS (other
study)
4 NICE, SMC
(expert
opinion), TLV
(longer-term
data)
Lack of
comparative
evidence
(phase II non-
comparative
pivotal trial)
 HAS
4 NICE (rarity,
early marketing
authorisation,
historical
controls)
4 SMC (rarity,
investigational
nature of the
treatment)
NICE National Institute for Health and Care Excellence, SMC Scottish Medicines Consortium, TLV Pharmaceutical Benefits Board, HAS Haute
autorite´ de Sante´
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categories, depending on the type of concern raised
(Fig. 2). This interpretative component occurs during the
deliberative process, during which these concerns may or
may not be considered acceptable based on the decision-
makers’ judgments, and, in some instances, on stakeholder
input. Their judgment may be influenced by ‘‘other con-
siderations’’ relating to disease and treatment characteris-
tics, which may not be captured in the standard estimates of
HTA. In this respect, 125 individual ‘‘other considerations’’
(Noc) were identified and grouped into 16 categories
(Fig. 2).
The correspondence analysis biplot illustrates agency-
specific risk preferences for these ten drugs, identifying the
types of concerns that one agency is more likely to raise
compared to another agency (Fig. 3). NICE was relatively
more concerned about population generalizability com-
pared to HAS, which was more concerned about issues
related to the treatment’s administration and provision
(horizontal axis). In contrast, SMC was relatively more
concerned about population generalizability and the treat-
ment’s benefit, and HAS about quality of life improvement
and safety (vertical axis). Conducting the same analysis
across the five study drugs commonly appraised, similar
results were seen, with additionally NICE being relatively
more likely to be concerned about sample size, HAS with
the duration of the study, and TLV about the treatment’s
administration and provision.
The same analysis was undertaken focusing on disease
and treatment characteristics, to understand the trends in
the types of value judgments made across settings and for
these ten drugs. Focusing on preferences relating to disease
characteristics (Fig. 4), NICE was relatively more likely to
account for existing treatment alternatives, clinical practice
and the impact of the disease on the patient’s surroundings,
whereas SMC and HAS were more likely to value rarity
and unmet need (horizontal axis). In contrast, HAS was
relatively more likely to value the nature of the disease
compared to SMC, which was more likely to value the
Fig. 2 Illustrates the number of cases where clinical uncertainties
and ‘‘other considerations’’ were identified influencing the decision
process in each country. In total 124 clinical uncertainties were
identified across the 35 country drug-indication pairs grouped into ten
categories, and 125 ‘‘other considerations’’ grouped into 16 cate-
gories. The latter 16 categories were further distinguished between
those that relate to living with the disease in question, from those to
taking the treatment. The representation of each group was ordered
such that the more frequently identified clinical uncertainty, disease-
related and treatment-related ‘‘other considerations’’ are represented
at the top of the graph
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condition’s rarity (vertical axis). Conducting the same
analysis across the five drugs appraised by all agencies,
TLV was additionally relatively more likely to value the
nature of the condition (e.g. disease severity). Correspon-
dence analysis examining relative value preferences around
treatment characteristics across the ten study drugs (Fig. 4)
showed that NICE was relatively more likely to value the
treatment’s safety and challenges in conducting RCTs, and
HAS the drug’s clinical benefit compared to the other
agencies. Conducting the same analysis across the five
drugs commonly appraised, similar conclusions were
reached where additionally TLV was relatively more likely
to value the treatment’s innovativeness.
The risk and value preferences identified across the ten
study drugs may have influenced these processes and
contributed to explaining cross-country differences.
Examining each of the concerns more in depth, only
14.5 % of the uncertainties identified (18 of the Nu = 124)
were commonly raised by all agencies, the remainder
having been raised by only one or some of the agencies.
This was further confirmed when measuring agreement in
the clinical uncertainties raised when appraising the same
evidence between two agencies, which ranged from poor to
less than expected by chance (j range -0.30 to 0.08)
(Table 3). In four cases, these differences in interpreting
the same evidence related to one of the main reasons for
the final decision (Table 2). For imatinib, the primary trial
length was deemed too short by NICE and SMC; this was
not highlighted by HAS. Additionally, the secondary end-
point ‘‘overall survival’’, considered by NICE as the main
parameter of interest, was not significantly improved,
negatively influencing the decision (e.g. imatinib was
rejected by NICE). For mannitol dry, the lack of
improvement in hospital days and antibiotic use reduction
was a concern for HAS, but not for NICE or SMC, further
illustrating the impact that agency-specific risk preferences
may have on decisions (HAS was relatively more con-
cerned about issues relating to the treatment’s administra-
tion and provision compared to the other agencies, Fig. 3).
The lack of improvement of HRQol negatively influenced
Fig. 3 This figure represents the correspondence analysis biplot
illustrating the relative associations between the HTA bodies and the
clinical uncertainties raised by each HTA body. Although the null
hypothesis of independence was rejected (v2 = 18.80; p = 0.4040), it
provides an indication about specific risk preferences. On the
horizontal axis (67.5 % of the variation), NICE is more likely to be
concerned about population generalizability and conformity to
clinical practice than HAS, which was more concerned about issues
relating to the treatment’s administration and provision, and the
duration of the trial. On the vertical axis (32.5 % of the variation),
SMC was more likely to be concerned about population generaliz-
ability and the treatment’s benefit, and HAS about quality of life
improvement and safety. Conducting the same analysis across the five
study drugs appraised by all agencies, a non-significant association
between variables was seen, likely due to the small sample size
(v2 = 27.95; p = 0.3451). Nevertheless, similar results were seen,
with additionally NICE being relatively more likely to be concerned
about sample size, HAS with the duration of the study, and TLV
about the treatment’s administration and provision. NICE National
Institute for Health and Care Excellence, SMC Scottish Medicines
Consortium, TLV Dental and Pharmaceutical Benefits Board HAS
Haute Autorite´ de Sante´, Qol quality of life, safety safety assessment,
design trial design, comparator comparator, duration duration of the
trial, administration administration and provision of the treatment,
benefit benefit of the treatment, size sample size, population
population generalizability, practice clinical practice
E. Nicod
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HAS’s decision (ASMR V, in line with findings from
Fig. 3), and was also raised by NICE, who acknowledged
that current measures do not fully capture the treatment and
disease effects; this was not highlighted by SMC.
Agreement between two agencies was reached if a
concern was considered addressed or not by both, and
disagreement if addressed by one and not the other. There
was agreement for 13 and disagreement for five of the 18
concerns commonly raised. When comparing agreement in
how agencies dealt with the same concerns across pairs of
countries, it varied, ranging between moderate to lower
than expected by chance, depending on the agencies (j
range -0.50 to 1.0) (Table 3).
Between 5 and 51 % of these clinical uncertainties
(Nu = 124), depending on the country, were addressed
through various means (51 % of nu
nice = 68 uncertainties
for NICE; 12 % of nu
smc = 60 for SMC; 47 % of nu
tlv = 21
for TLV; and 5 % of nu
has = 44 for HAS). First, stakeholder
input was used to confirm the plausibility of a (uncertain)
clinical claim. Second, the uncertainties were raised but
nevertheless considered acceptable by the Appraisal
Committee. Third, greater uncertainty was accepted given
the rarity of the condition or accounting for non-primary
evidence. In three cases, differences in the interpretation of
evidence were also one of the main reasons for the final
recommendation (Table 2). Two of these were based on
expert opinion: the risk of bronchospasms was deemed
minimal by NICE clinical experts for mannitol dry, and the
risk of interactions with other treatments was deemed
minimal by clinical experts from NICE and SMC for
mifamurtide. In one case (trabectedin), the lack of com-
parative data for the primary phase II trial was a concern
for all but was addressed differently. It was deemed
acceptable given the rarity of the condition and
Fig. 4 Correspondence analysis biplot illustrating the relative asso-
ciations between the HTA bodies and disease (left) and treatment
characteristics (right). The figure to the left represents the statistically
significant relative associations between the HTA bodies and disease
characteristics (v2 = 40.05; p = 0.0008). On the horizontal axis
(72.1 % of the variation), NICE was more likely to account for
existing treatment alternatives, clinical practice and the impact of the
disease on the patient’s surroundings, whereas SMC and HAS for
rarity and unmet need. On the vertical axis (27.9 % of the variation),
HAS was more likely to value the nature of the disease, and SMC the
rarity of the condition. Conducting the same analysis across the five
drugs appraised by all agencies, associations were statistically
significant (v2 = 47.37; p = 0.0008). Preferences for NICE, SMC
and HAS were similar, whereas TLV was relatively more likely to
value the nature of the condition (e.g. disease severity). The figure to
the right illustrates the significant relative associations between the
HTA bodies and treatment characteristics (v2 = 29.46; p = 0.0011).
On the horizontal axis (93.5 % of the variation), NICE was relatively
more likely to value the treatment’s safety and challenges in
conducting RCTs, and HAS the drug’s clinical benefit compared to
other agencies. On the vertical axis, relationships were relatively less
meaningful given that only 6.5 % of the variation was captured.
Conducting the same analysis across the four drugs appraised by all
four agencies, similar conclusions were reached (v2 = 21.05;
p = 0.0496). Additionally, TLV was relatively more likely to value
the innovativeness of the treatment compared to the other agencies.
NICE National Institute for Health and Care Excellence (NICE), SMC
Scottish Medicines Consortium, TLV Dental and Pharmaceutical
Benefits Board, HAS Haute Autorite´ de Sante´, rare rarity, small
sample size, orphan drug, unmet unmet need, nature nature of the
condition and its impact on the patient, pathway complex pathway, no
best practice, alternative issues around current alternatives, cost cost
burden of current treatment alternatives, nature_surr disease nature
affecting the patient’s surroundings, withdraw withdrawals from
effects not related to the treatment, mgt_comp issues around the
management of treatment alternatives, benefit clinical benefit and type
of benefit, outcome indirect benefits from the treatment, innovative
innovative nature of the treatment, AES adverse events from the
treatment manageable or non-significant, RCT challenges in conduct-
ing RCTs, indications additional indications of treatment
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investigational nature of the treatment by NICE and SMC;
additionally NICE accounted for registry data as historical
controls; in contrast, it was not deemed acceptable by HAS.
A number of additional ‘‘other considerations’’ were
also put forward by the agencies as one of the reasons for
the final recommendation, and associated with differing
final outcomes. In a number of cases, greater flexibility was
granted to the ICER and uncertainty on the basis of the
following considerations that relate to agency-specific
modulators: (a) SMC modifiers (5/10 drugs), (b) NICE end-
of-life supplementary advice (4/10 drugs) [43], or (c) dis-
ease severity at TLV (all five drugs). In particular, four
drugs fulfilled the NICE end-of-life criteria, where three
were considered cost-effective with an ICER lower than
£50,000/QALY (lenalidomide, azacitidine, trabectedin),
and one not cost-effective with an ICER greater than
£50,000/QALY (everolimus). Similarly, the high ICERs
were accepted by SMC for lenalidomide and azacitidine,
given the SMC modifiers, and by TLV for lenalidomide,
given the severity of the disease.
There were also a number of process-specific modula-
tors rendering the ICER more acceptable, that contributed
to explaining cross-country differences: (a) patient access
schemes at NICE (7/10 drugs) and SMC (3/10 drugs),
(b) lower discount rates accepted by NICE and SMC (1/10
drugs), (c) imposing a restriction by NICE (3/10 drugs) and
SMC (4/10 drugs), (d) imposing a re-assessment by TLV
(2/5 drugs) and HAS [8/10 under a temporary authorisation
scheme (ATU)]. For example, uncertainty was addressed
for lenalidomide by imposing a third line restriction (SMC,
NICE), or a future re-assessment once more evidence is
collected (TLV). Another modulating factor was the ability
to implement a lower discount rate on costs and effects
captured in the model, as was seen for mifamurtide by
NICE and SMC, whereas the high ICER was acceptable for
TLV given the severity of the condition, but was rejected
by HAS for the reasons discussed in the next paragraph.
A final contrast was seen when assessing cost-effec-
tiveness versus clinical benefit, also resulting in opposite
conclusions. A number of compounds rejected by NICE
Table 3 Agreement between HTA bodies in the uncertainty raised about the same evidence (raised versus not raised); and when the same
uncertainty was raised, agreement about how it was dealt with (addressed versus not addressed)
Kappa scores
(95 % confidence intervals)
standard error (SE)
number of observations (n)
Level of agreement in the uncertainties raised (raised versus not raised)
Level of agreement in interpreting the same
uncertainties
(addressed versus not addressed)
NICE SMC TLV HAS
NICE 1 -0.06
(-0.235 to
0.124)
SE = 0.091
n = 117
-0.15
(-0.434 to
0.143)
SE = 0.147
n = 44
0.01
(-0.172 to
0.183)
SE = 0.090
n = 110
SMC 0.51
(0.203–0.814)
SE = 0.156
n = 29
1 -0.30
(-0.588 to
0.018)
SE = 0.145
n = 43
0.08
(-0.108 to
0.261)
SE = 0.094
n = 110
TLV 1.00
(1.00–1.00)
SE = 0.00
n = 7
0.72
(0.232–1.00)
SE = 0.249
n = 7
1 -0.07
(-0.324 to
0.180)
SE = 0.128
n = 44
HAS -0.08
(-0.227 to
0.067)
SE = 0.075
n = 24
0.18
(-0.272 to
0.630)
SE = 0.230
n = 22
-0.50
(-1.00 to 0.235)
SE = 0.375
n = 4
1
Cohen’s kappa scores (j) rank agreement levels from poor (j = 0) to perfect agreement (j = 1) and where minus values of j correspond to
cases when agreement was less than expected by chance
NICE National Institute for Health and Care Excellence (NICE), SMC Scottish Medicines Consortium, TLV Dental and Pharmaceutical Benefits
Board, HAS Haute Autorite´ de Sante´
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and SMC received an important SMR rating with a
65–100 % coverage rate (e.g. eltrombopag, everolimus,
imatinib), and a high ASMR rating associated with a more
favourable pricing scheme (e.g. eltrombopag, imatinib).
The negative recommendations issued by NICE and SMC
were due to the high ICER and main parameter of interest
included. There were also drugs positively appraised by
NICE and SMC, which received very low SMR ratings
[e.g. moderate (30 %) and weak (15 %) coverage] and an
ASMR V or a rejection by HAS (e.g. mannitol dry, ofa-
tumumab, mifamurtide). This was because of the lack of
comparative data as a result of the early marketing
authorisation granted (ofatumumab) and early scientific
advice received (mannitol dry), or the highly uncertain
evidence presented (mifamurtide). Mannitol dry and
mifamurtide also had in common that they were the only
two drugs that were not part of the temporary authorisation
scheme (ATU) in France.
Discussion and policy implications
This study adopted a mixed methods research design based
on an existing methodological framework to investigate
HTA decision processes for ten drug and indication pairs
across four countries, and showed important variations and
contradictory trends across countries. Differences at each
stage of the HTA process were identified, partly explaining
the reasons for differing HTA recommendations across
countries, while illustrating the complexity of these pro-
cesses. First, heterogeneity was seen in the evidence
accounted for, in the interpretation of the same evidence,
and in the different ways of dealing with the same uncer-
tainty (Table 2). These were influenced by the evidentiary,
risk and value preferences identified across the ten study
drugs. The differences in interpreting the same evidence
were partially explained by varying levels and types of
stakeholder input, the consideration (or not) of the drug’s
orphan status or investigational nature, the consideration of
additional qualitative criteria (e.g. innovation, unmet need),
the presence of another study, or as part of the decision-
maker’s judgment during deliberation. There were also a
number of decision modulators that contributed to a greater
acceptance of uncertainty or higher and uncertain ICERs.
These included agency-specific modulators, pertaining to
agency-specific elicited or non-elicited societal prefer-
ences, such as the SMC modifiers, NICE’s end-of-life
supplementary advice and disease severity for TLV. There
were also process-specific modulators, which included the
ability to implement patient access schemes or lower dis-
count rates, or to impose restrictions or future re-assess-
ments. There were also consequences from the HTA
approach used (clinical or cost-effectiveness) on the final
decision.
Results from this in-depth analysis of ten orphan drugs
suggest that HTA is not a simple analysis of clinical and/or
cost-effectiveness, but remains a flexible process subject to
the decision maker’s interpretation about uncertainty and
social values as part of the deliberative process of HTA.
This study contributes to shedding light on some of the
factors being accounted for, which may not necessarily be
explicitly defined as part of the decision process. Policy-
makers should be aware of the more comprehensive set of
factors accounted for in these decisions, and the different
ways of applying HTA, including how countries dealt with
the issues specific to—but not limited to—orphan drugs.
The implications of these findings are discussed here,
together with the study limitations.
Contrasting applications of HTA
A first contrast was seen between the HTA recommenda-
tions driven by cost-effectiveness and those by clinical
benefit. Some drugs with a recognised positive clinical
benefit in France were rejected in some, but not all, of the
other countries partly due to their high ICER (e.g. ever-
olimus, eltrombopag). This finding is in line with one study
that compared NICE coverage and HAS ASMR decisions
for a sample of anticancer drugs, showing a significant
association between the QALY gain and ASMR ratings,
but none when accounting for costs (ICER) [8]. This also
has implications on price, which is driven by the ASMR
assessment. Economic evaluation has recently been
implemented by HAS to support price negotiations for
those drugs with an ASMR I-III rating (significant to major
improvement in clinical benefit). In such cases, the eco-
nomic evaluation acts as an additional criterion to be
accounted for by the French Economic Committee for
Healthcare Products (CEPS) when negotiating prices, giv-
ing more weight to the concept of value and value for
money. This two-step approach may, however, have neg-
ative implications on the price of those orphan drugs
considered to have a minor or no improvement in clinical
benefit (ASMR IV-V). As illustrated in the case studies
analysed, those drugs with very uncertain evidence (due to
the lack of comparative data) received low ASMR ratings,
where their price will be set lower than comparator prices.
In the other study countries, their assessments based on
economic evaluation approaches allow for various tech-
niques to deal with uncertainty (e.g. sensitivity analysis),
which subsequently may also influence the ICER estimate
and drug pricing.
Further contrasts were also seen within those countries
assessing cost-effectiveness. The acceptability of the
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ICER, based on similar economic models and comparators,
differed due to the agency-specific or process-specific
modulators identified: (a) disease severity for TLV,
(b) SMC modifiers, (c) patient access schemes, (d) NICE
end-of-life criteria, (e) imposing restrictions, or (f) contin-
uous data generation and future re-assessment. The first
four reflect adjusted willingness-to-pay thresholds and
special considerations for orphan drugs, while the latter
two cases relate to the ability to modulate the ICER by
identifying circumstances or subgroups for which the
treatment is cost-effective, or accepting greater uncertainty
for a limited period of time until more evidence is gener-
ated. Findings for Sweden are in line with a recent study
that demonstrated the positive impact of disease severity on
reimbursement decisions, despite severity not being
explicitly defined [44]. The ability to implement patient
access schemes is another way of improving the cost-ef-
fectiveness and/or uncertainty [45], and providing earlier
access to these treatments [46]. Their effects on innovation
and expected returns are still unclear [47], and a number of
issues around their implementation have been already
noted [48]. Additionally, in those countries that have the
ability to implement process-specific modulators (e.g.
patient access schemes), this study showed that their
application was not the same nor consistent across coun-
tries or drugs.
Dealing with rare conditions
Results illustrate the type of issues encountered when
dealing with orphan drugs in terms of the nature of the
evidence presented (e.g. sample size, phase II primary
trials, subgroup data, surrogate endpoints, lack of com-
parative data) and the types of issues highlighted by the
HTA bodies (e.g. small sample size, insufficient statistical
power, surrogate endpoints, subgroup data, etc.), corre-
sponding to what characterises orphan drugs [49, 50].
Different ways in dealing with this imperfect evidence
were seen. In some cases, these issues relating, but not
specific to orphan drugs were considered accept-
able through various means as highlighted in this study.
This included the specific consideration of the condition’s
rarity or the recognised difficulties in recruiting sufficient
patient numbers in trials, as highlighted by TLV for
eltrombopag or NICE for mifamurtide and romiplostim. In
other circumstances (e.g. dealing with subgroup popula-
tions), some issues remained inconclusive for all because
of their lack of statistical power or retrospective nature
(e.g. azacitidine or mannitol). When comparing the
prevalence rates used by SMC in their budget impact
analysis and the HTA recommendations issued, two
observations arise. The three drugs treating less than 20
patients per year (ofatumumab, mifamurtide, trabectedin)
had generally poorer outcomes: they all received the
poorest ASMR (V) rating, and were more likely to be
rejected by the other agencies (ofatumumab by all, tra-
bectedin by SMC). This was a consequence of the lower
quality of the evidence from small sample sizes or the lack
of comparative data. In the ‘‘more prevalent’’ rare condi-
tions analysed (between 200 and 300 patients per year in
Scotland), similar issues were encountered but to a lesser
extent were these linked to the small sample size (el-
trombopag, mannitol dry). These experiences could be a
good starting point for generating the circumstances under
which small sample sizes or other issues specific to rare
diseases may be acceptable due to the rarity of the condi-
tion, also ensuring these are accounted for consistently
across cases.
Results also suggest possible misalignments between the
incentives implemented for marketing authorisation and
their effect at HTA level. For three drugs, the evidence
presented was very uncertain due to its low quality and lack
of comparative data (e.g. mannitol dry, ofatumumab, tra-
bectedin). This was a consequence of the early marketing
authorisation granted or early scientific advice received,
which negatively influenced the HTA decisions made: low
ASMR ratings (V) in France and rejected in the other
countries. Two exceptions, however, were identified
(NICE’s recommendations for mannitol dry and trabecte-
din), where uncertainty was deemed acceptable thanks to
the different mechanisms modulating the ICER or to the
consideration of other forms of evidence (e.g. historical
controls, other considerations). These examples may con-
stitute ways forward in dealing with such scenarios in the
future. Additionally in France, all study drugs were made
available as part of their temporary authorisation
scheme (ATU), with the exception of mannitol dry and
mifamurtide. The former received an ASMR V rating and
the latter was rejected, which occurs very rarely in France.
This may imply that continuous data collection is an
additional factor that contributes to accepting greater
uncertainty in France.
HTA methodological challenges
RCT weaknesses are well known and include limitations
around safety and generalizability to heterogeneous popu-
lations or clinical practice, as well as the cost to conduct
them [14]. Similar issues were identified in this study (e.g.
generalizability to local population, non-inclusion of cer-
tain patient subgroups or subgroup heterogeneity, trial
population non-representative of the indication under
review, or imbalances in the characteristics or responses
across the different subgroups). Given the preference for
RCTs observed and the inclusion of these trial results as
main parameters of interest in the economic models, the
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above concerns identified and the diverging ways in deal-
ing with these emphasise the need to recognise comple-
mentary forms of robust and valid evidence [14]. Apart
from a few cases (e.g. expert opinion to confirm general-
izability), this was not seen in practice given the limited
role of non-phase III evidence in the assessment of clinical
benefit and cost-effectiveness observed in this study. The
uptake of such forms of evidence is still modest and likely
due to the lack of expertise around dealing with a variety of
types of observational evidence including those based on
real world data such as electronic patient records, [51] or
patient-reported outcomes [52]. Their role, however, is to
be stressed given their potential use for policy making in,
for example, the value-based system or process for highly
specialised medicines at NICE, the patient and clinician
engagement (PACE) programme at SMC, the use of
managed entry agreements [47] and, more recently, the
introduction of a pilot study on adaptive licensing at the
EMA [53, 54]. With these new developments, the envi-
ronment is increasingly relying on expert opinion, obser-
vational studies and real world data [55], which could
provide insights about treatment effectiveness, the burden
of illness, the nature of a condition, or the indirect health
care costs and benefits from taking the treatment and
feeding it into a more adaptive model of HTA [56]. This is
already in place in some countries such as Sweden or
France (under the ATU scheme), which has contributed to
dealing with uncertainty in some of the cases evaluated
without imposing additional conditions or restrictions.
This study identified differences across countries in the
type of evidence that is considered appropriate and in
interpreting the same evidence, contributing to explaining
different HTA recommendations. A more formalised and
consistent recognition of the acceptability criteria for evi-
dence and uncertainty is needed, which could be achieved
by generating criteria based on past decisions such as the
specific circumstances (e.g. early marketing authorisation)
or quality standards (e.g. reliability, validity) required. The
agency-specific risk and value preferences identified in this
study could also be a good starting point for shedding light
on the more common circumstances already arising in the
different countries.
Practical implications
This research is in line with the recognised need to better
understand pricing and reimbursement systems through
cross-country learning and sharing of experiences [57]. It
may be useful for European-level initiatives, such as the
pilot for a common European HTA (EUnetHTA), as it
sheds light on the different applications of HTA and the
reasons for differences in the HTA recommendations
made, which can feed into discussions when seeking
greater consensus across Member States. It may also feed
into the new programmes that have since been imple-
mented for orphan drugs (PACE programme at SMC), and
for ultra-orphan drugs (NICE’s Highly Specialised Tech-
nology (HST) programme, SMC’s ultra-orphan drug deci-
sion framework), as well as HAS’s recent requirement for
an economic evaluation. These recent developments all
have in common (with the exception of the HST pro-
gramme) that they are add-ons to conventional pro-
grammes. Therefore, better understanding of how value is
being assessed within these conventional programmes and
the reasons for cross-country differences is relevant to
identifying issues and potential ways forward for their
continuous improvement, while acting as a reference when
evaluating these new programmes. This is all the more
significant given their recentness, where little is known
about their impact.
Results and the systematic approach used may also feed
into other forms of research around priority setting. The
retrospective identification of the criteria driving previous
decisions, applied in this study, is also recognised as one
approach to criteria elicitation for multiple criteria decision
analysis (MCDA) when used for priority setting [58].
When comparing the criteria identified in this study to
those elicited by the EVIDEM project for the purpose of
MCDA, similarities were seen. For example, unmet need
was categorised as unmet need in efficacy, in safety, in
patient-reported outcomes and patient demand [59]. This
study identified the different expressions of unmet need,
such as: the importance of new treatment options, the lack
of (satisfactory) treatment alternatives, alternatives not
routinely available, the need to improve therapeutic man-
agement, and so forth. Identifying the different expressions
of such criteria in practice may feed into defining their
attribute levels during the criteria elicitation processes (e.g.
MCDA, discreet choice experiments).
A more recent study developed a value proposition
based on 19 social value arguments about orphan drug
reimbursement decisions, summarised into four value-
bearing factors (e.g. disease-related, treatment-related,
population-related and socio-economic factors) [60]. Most
of these factors were identified in this study (Fig. 2), with
the exception of the identifiability of treatment beneficia-
ries, the impact on the distribution of health, or any of the
socio-economic factors. These corroborate the finding’s
content validity, and showcase the ability to identify how
these factors are expressed in practice. Another example is
the second component, ‘‘decision-making process’’, of the
evidence-informed framework developed by Dr Stafinski
and colleagues, comprising a list of 7 questions important
for resource allocation decisions, and which corresponds to
the decision-making processes analysed in this study [61].
This research and the approach used allows one to identify
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how some of the key questions are expressed in practice
during these decision processes, namely those about ‘‘in-
formation inputs’’ and ‘‘information sources’’, ‘‘social
value judgements’’ and ‘‘deliberations’’, which correspond
to the ‘‘evidence’’ and ‘‘interpretation of the evidence’’
components, respectively, from the methodological
framework applied in this study [4].
Limitations and need for further research
This research is not without its limitations. First, the data
was mainly collected from secondary sources. It would
have been preferable to have full information about the
submissions (e.g. manufacturer submission), but this was
not possible in the current scheme. The information
obtained by applying the methodological framework was
unavoidably limited by the level of detail provided in the
HTA reports and whether the framework captures all
aspects of the decision-making process [4]. The informa-
tion published was assumed to be transparent and reflect
the main determinants driving the decisions (transparency
directive). The analysis of these published documents was
considered to provide sufficient detail and explain how
decisions were reached. Additionally, triangulation with
other data sources ensured that sufficient detail was cap-
tured for each case study [e.g. HTA reports, additional
material, and input from HTA experts (Advance-HTA
consortium, conferences)]. Results were also presented to
and discussed with the HTA bodies, ensuring that the
interpretation of the decisions made by the research was
accurate. Second, there were sampling issues arising from
differences among the four agencies in the way they select
topics for their assessments. Despite these differences, a
suitable sample was identified. Third, this research focused
specifically on orphan drugs, which undergo the same HTA
process as drugs for more common conditions. Some of the
findings may also be applicable to these more common
conditions. One component of the analysis did focus on
identifying those challenges that are specific, but not nec-
essarily always unique to, dealing with these rarer condi-
tions, and draw key lessons from these. A final limitation is
the relatively small sample size, which does not allow for
multivariate regression analysis. However, this research
resulted in meaningful outputs derived from a more in-
depth and qualitative component showing that differences
across countries do matter. A more structured understand-
ing of the possible explanations for differences were
derived from the findings, allowing for subsequent more
quantitative analyses to focus on certain aspects of the
decision-making process across a greater sample. Further
research could look at the drivers of these differences
across a larger sample of drugs and therapy areas using
multivariate regression analysis for a greater generalisation
of the results, by extending it to other types of drugs to
assess how different agencies assess different drug and
disease characteristics. In order to maintain the depth and
breadth of the analysis building on the methodological
framework used in this study, it is highly recommended to
begin by prioritising the qualitative strand to ensure that the
depth of the processes are captured and comparable across
settings.
Conclusions
This research contributes to better understanding, in a
systematic manner, what is driving these complex decision
processes in practice, and why countries make different
decisions. It also contributes to identifying those factors
beyond the standard clinical and cost-effectiveness tools
used in HTA, how they influenced the decision and how
they were provided. The implications of this research are
all the more important given the shift towards niche mar-
kets and personalised medicine, where an increasing
number of the treatments undergoing regulatory and cov-
erage processes are characterised by some of the important
issues discussed in this paper.
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